scholarly journals Role of gabapentin enacarbil XR in restless legs syndrome

2012 ◽  
pp. 201 ◽  
Author(s):  
Sheila Sivam ◽  
Sivam ◽  
Sheila Sivam
Keyword(s):  
Restless Legs Syndrome ◽  
Gabapentin Enacarbil ◽  
Restless Legs

scholarly journals Review of the Treatment of Restless Legs Syndrome: Focus on Gabapentin Enacarbil

2012 ◽  
Vol 4 ◽  
pp. JCNSD.S9107 ◽  
Author(s):  
Rachel A. Burke ◽  
Michele A. Faulkner
Keyword(s):  
Clinical Trials ◽  
Restless Legs Syndrome ◽  
Dopamine Agonists ◽  
First Line ◽  
Gabapentin Enacarbil ◽  
Restless Legs ◽  
First Line Therapy ◽  
Line Therapy ◽  
Dopaminergic Agent

The FDA approved gabapentin enacarbil in 2011 as the first non-dopaminergic agent for the treatment of restless legs syndrome (RLS) symptoms. Although gabapentin enacarbil is a pro-drug of gabapentin, its pharmacokinetics differ. Absorption of gabapentin enacarbil is more predictable, and inter-patient variability in bioavailability is lower than that of gabapentin. Studies have demonstrated superiority of gabapentin enacarbil compared to placebo. Comparisons to currently available RLS treatments are lacking, but clinical trials demonstrate comparable improvement in RLS symptoms to the dopamine agonists ropinirole and pramipexole, which are usually considered first-line therapy for daily RLS symptoms. Gabapentin enacarbil was well tolerated in clinical trials. The role of the drug in RLS treatment remains undefined, although it will likely be used as an alternative for refractory RLS when other treatments have failed. Additionally, gabapentin enacarbil may be recommended for patients with daily RLS symptoms that are less intense or are associated with pain as an alternative to dopamine agonists.

A 52-Week Study of Gabapentin Enacarbil in Restless Legs Syndrome

2011 ◽  
Vol 34 (1) ◽  
pp. 8-16 ◽  
Author(s):  
Aaron L. Ellenbogen ◽  
Stephen G. Thein ◽  
David H. Winslow ◽  
Philip M. Becker ◽  
Jerry M. Tolson ◽  
...  
Keyword(s):  
Restless Legs Syndrome ◽  
Gabapentin Enacarbil ◽  
Restless Legs

scholarly journals The role of BTBD9 in the cerebral cortex and the pathogenesis of restless legs syndrome

2020 ◽  
Vol 323 ◽  
pp. 113111 ◽  
Author(s):  
Shangru Lyu ◽  
Hong Xing ◽  
Mark P. DeAndrade ◽  
Pablo D. Perez ◽  
Keer Zhang ◽  
...  
Keyword(s):  
Cerebral Cortex ◽  
Restless Legs Syndrome ◽  
Restless Legs

scholarly journals 0790 The Clinical Significance of Hepcidin as a Predictive Value for Treatment Responses in Restless Legs Syndrome

SLEEP ◽  
2020 ◽  
Vol 43 (Supplement_1) ◽  
pp. A300-A301
Author(s):  
H Im
Keyword(s):  
Restless Legs Syndrome ◽  
Iron Homeostasis ◽  
Dependent Manner ◽  
Healthy Controls ◽  
Restless Legs ◽  
Inflammatory Processes ◽  
Drug Naïve ◽  
Therapeutic Responses

Abstract Introduction Restless legs syndrome (RLS) is a common sensory motor neurological disorder that is related to iron-dopamine dysregulation and immune system alteration. Hepcidin is the key regulatory hormone of systemic iron homeostasis and is related to inflammatory processes. We aimed to evaluate the clinical utility of hepcidin as a diagnostic biomarker and index of therapeutic responses in RLS patients after dopaminergic treatment. Methods Non-anemic and drug-naive RLS patients (n=18) and healthy controls (n=15) were enrolled. Hepcidin (pre-prohepcidin) and iron-related values in serum were measured upon the first visit in both groups and 12 weeks later after dopaminergic treatment in 12 RLS patients. Information about sociodemographic characteristics, sleep-related profiles, mood, and anxiety was obtained upon the first visit in all participants as well as after treatment in RLS patients. Results Hepcidin levels exhibited no significant differences between patients with drug-naïve RLS and healthy controls at a diagnosis (7.1 ± 2.4 vs. 7.0 ± 3.2 ng/ml, p = 0.978). Decreased hepcidin levels were significantly associated with decreased RLS severity (β = 0.002, 95% CI = 0.00−0.00, p = 0.005) and improved quality of life (β = 0.002, 95% CI = 0.00−7.01, p = 0.044) in a dose-dependent manner after 12 weeks of treatment with a dopamine agonist. This association was independent of age, sex, inflammatory markers, sleep quality, insomnia, daytime sleepiness, depression, and anxiety. Conclusion This study demonstrates a role of hepcidin as a predictor of therapeutic responses in RLS patients. Support This work was supported by the Korea Health technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, South Korea [grant number HI17C2072].

Sign in / Sign up

Export Citation Format

Share Document